GlassScriptPhysician profile
Ahmed Rehan
NPI 1700846987
$2,126.42
in general payments reported to CMS, 2019-2025
24 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $156 · 2021: $120 · 2022: $256 · 2023: $645 · 2024: $354 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.53 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $504.99 | 2019-2025 | Parsabiv, Tavneos, Aranesp |
| Fresenius USA Marketing, INC. | $351.54 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $170.46 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $141.33 | 2022-2025 | Acthar |
| Ardelyx, INC. | $124.40 | 2024 | Xphozah 30 Mg |
| Vifor Pharma, INC. | $119.21 | 2021-2024 | Veltassa |
| Glaxosmithkline, LLC. | $98.17 | 2021-2023 | Benlysta |
| Novo Nordisk INC | $68.42 | 2023-2024 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $65.16 | 2024-2025 | |
| Akebia Therapeutics INC | $54.30 | 2019-2021 | |
| Covidien LP | $52.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $51.88 | 2020-2023 | Farxiga |
| Calliditas Therapeutics US INC. | $48.03 | 2022-2023 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $44.28 | 2023-2025 | Lupkynis |
| Ani Pharmaceuticals, INC. | $36.44 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $32.65 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $27.14 | 2023 | Envarsus |
| Lilly USA, LLC | $25.65 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.55 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.79 | 2024 | Jynarque |
| Abbvie INC. | $18.85 | 2022 | |
| Philips North America LLC | $17.39 | 2020 | |
| Nxstage Medical, INC. | $16.63 | 2019 | |
| Amarin Pharma, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Rehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.